MD Anderson Cancer Center: Investigational Drug With Immunotherapy May Provide Therapeutic Opportunity for Patients Treated for Kidney, Lung Cancer
September 26, 2019
September 26, 2019
HOUSTON, Texas, Sept. 26 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
- Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase IB study
* * *
Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney canc . . .
* * *
- Pegilodecakin with pembrolizumab and nivolumab shown to be safe in Phase IB study
* * *
Pegilodecakin, a first-in-class drug currently in clinical trials, has shown positive safety results and may offer a potential new treatment avenue for patients with non-small cell lung cancer (NSCLC) and kidney canc . . .